Reanalysis of controversial meta-analysis says writing off rosiglitazone may be premature

That article was based on a meta-analysis conducted by Dr. Steven Nissen and Kathy Wolski of 42 clinical trials involving 27,847 patients for whom rosiglitazone was prescribed.

Now, a re-analysis of the data used in the Nissen and Wolski analysis - using different statistical models - suggests that the earlier methodology may have resulted in inflated risk estimates. The new analysis, conducted by researchers at Cedars-Sinai Medical Center, concludes "that only prospective clinical trials designed for the specific purpose of establishing the cardiovascular benefit or risk of rosiglitazone will resolve the controversy about its safety."

In an Annals of Internal Medicine article, cardiologists George Diamond, M.D., and Sanjay Kaul, M.D., describe additional analyses that provide different perspectives on rosiglitazone's safety issues. "Uncertain Effects of Rosiglitazone on the Risk of Myocardial Infarction and Cardiovascular Death" appeared online Aug. 7.

Both physicians testified Monday, July 30, before a Food and Drug Administration advisory committee reviewing the data on rosiglitazone's safety. At the conclusion of hearings, the panel recommended that Avandia carry new risk warnings but stopped short of calling for the drug to be removed from the market.

"The original meta-analysis employed one statistical model, but there are other approaches that deserve consideration as well. Only when different methods give us the same answers should we be confident in the results," say Diamond and Kaul.

In their study, Nissen and Wolski pulled together data from wide-ranging clinical trials that were not necessarily designed to track heart attacks and cardiovascular death. In addition, most of the trials did not report occurrence of any heart attack or cardiovascular death. In this type of "sparse data" situation, the statistical model employed by Nissen and Wolski tends to overestimate risk, and some experts call for applying a "correction factor." When the "corrected" data were recomputed using a different model, risk estimates were found to be lower.

"Although the risks were still elevated, they were no longer statistically significant. There was greater uncertainty about the risk associated with rosiglitazone than was originally reported, with neither increased nor decreased risk established conclusively," the authors say.

Even with the re-analysis, Diamond and Kaul are concerned about the practicality and reliability of combining data from 42 studies that had a variety of trial designs and protocols. Therefore, they believe, the controversy over rosiglitazone's risk will only be resolved when clinical trials focusing on all these issues are completed.

Source: Cedars-Sinai Medical Center

Beta-blockers reduce mortality in patients with COPD after vascular surgery
In the first study to directly examine the effects of beta-blockers on surgical patients with chronic obstructive pulmonary disease (COPD), researchers have found that, contrary to previous thought, beta-blockers significantly reduce mortality in COPD patients.
Popular COPD treatment increases risk for cardiac events, cardiac death
New research out of Wake Forest University School of Medicine shows that use of the most commonly prescribed once-a-day treatment for chronic obstructive pulmonary disease (COPD) for longer than one month increases the risk of cardiovascular death, heart attack or stroke by more than 50 percent.
Healthy people with elevated levels of uric acid are at risk of developing kidney disease
Elevated uric acid levels in the blood indicate an increased risk of new-onset kidney disease, according to a study appearing in the December 2008 issue of the Journal of the American Society Nephrology (JASN). The results suggest that it may be appropriate to prescribe uric acid–lowering drugs, such as allopurinol and probenecid, to these otherwise healthy individuals.
Top-selling prescription drug mismarketed to women
Lipitor has been the top-selling drug in the world and has accounted for over $12 billion in annual sales. It has been prescribed to both men and women to lower cholesterol and reduce the risk of heart attack and stroke in patients with common risk factors for heart disease. However, a new study appearing in the Journal of Empirical Legal Studies was unable to find high quality clinical evidence documenting reduced heart attack risk for women in a primary prevention context. Furthermore, advertising omits label information relevant to women.
Old and new therapies combine to tackle atherosclerosis
Futuristic nanotechnology has been teamed with a decades-old drug to beat atherosclerotic plaques in research conducted at Washington University School of Medicine in St. Louis.
Depressed dialysis patients more likely to be hospitalized or die
Dialysis patients diagnosed with depression are nearly twice as likely to be hospitalized or die within a year than those who are not depressed, a UT Southwestern Medical Center researcher has found.
Community-based diabetes prevention program shows promise
With over 60 million Americans diagnosed with prediabetes, putting them at increased risk for diabetes, cardiovascular events and other obesity-related ailments, finding ways to help large populations avoid these complications is an important initiative. In an article published in the October 2008 issue of the American Journal of Preventive Medicine, researchers from the Indiana University School of Medicine report that organizations such as the YMCA can be an effective vehicle for diabetes-prevention education.
Class of diabetes drugs carries significant cardiovascular risks
A class of oral drugs used to treat type 2 diabetes may make heart failure worse, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.

Reanalysis of controversial meta-analysis says writing off rosiglitazone may be premature

Related stories:

News discussion: